Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports

Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melanoma (MM). Autoimmune adverse reactions are very co...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomsen, Kenneth, Diernaes, Jon, Øllegaard, Trine Heide, Spaun, Eva, Vestergaard, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047493/
https://www.ncbi.nlm.nih.gov/pubmed/30022934
http://dx.doi.org/10.1159/000489661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047493/
https://www.ncbi.nlm.nih.gov/pubmed/30022934
http://dx.doi.org/10.1159/000489661

Ejemplares similares